Advertisement
Advertisement
U.S. markets closed
Advertisement
Advertisement
Advertisement
Advertisement

Theravance Biopharma, Inc. (TBPH)

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
Add to watchlist
10.14+0.03 (+0.30%)
At close: 04:00PM EDT
10.14 0.00 (0.00%)
After hours: 04:14PM EDT
Advertisement

Yahoo Finance will soon be upgrading our Conversations message board platform to provide a better experience for our users. Only comments published since April 21, 2021 will be visible on Yahoo Finance after the upgrade. If you wish to download and save any of your older comments, please submit a request via the Privacy Dashboard by no later than Sept. 30.

Sign in to post a message.
  • S
    SW
    Sept. 28, 2022 Theravance Biopharma today announced a "modified Dutch auction" tender offer to purchase up to $95 million of its ordinary shares, par value $0.00001 per share.

    Upon the terms and subject to the conditions set forth in the Company's Offer to Purchase, dated September 28, 2022 and the related Letter of Transmittal, the Company is offering to purchase up to $95 million of its Shares, at a purchase price not greater than $10.50 nor less than $9.75 per Share, in cash, less any applicable withholding taxes and without interest. The Offer will expire at midnight, New York City time, at the end of the day on November 10, 2022, or any other date and time to which the Company extends such Offer, unless earlier terminated.
  • t
    the_entitled
    Where’s Horseshoe?
  • M
    Mike
    Congrats to this outstanding mgmt. running a debt free company now.
    Redemption of 230mio senior notes spells annual savings of 7,5mio.
    Well done.
    Annual savings in interest payments o
  • M
    Mike
    Listening to the CC. I've rarely seen a management so good.
    That move to de leverage the balance sheet, and going cash flow positive soon is laudable beyond words. (by way of contrast other mgmts drown their shareholders in more & more debt.)
    The rising COPD incidence courtesy of the "fuxx side effects" is grist to the mill and conducive to earnings of Yupelri.
    Mgmt, I salute you.
    Shorts, I pity y'all.
    Bullish
  • M
    Mike
    Theravance now with a clean debt free balance sheet, 430mill in cash, cash flow positive in Q3. Share price = 6$ is cash, 3 $ for existing income stream, intellectual property, pipeline.
    Special dividend, share buyback?
    BUYOUT?
    Completion of Acquisition or Disposition of Assets.

    On July 20, 2022, Theravance Biopharma, Inc., a Cayman Islands exempted company (“TBPH”), completed the previously disclosed sale of its 2,125 Class B Units and 6,375 Class C Units (collectively, the “Units”) of Theravance Respiratory Company, LLC, a Delaware limited liability Company (“TRC”), held by its wholly owned subsidiaries, Theravance Biopharma US Holdings, Inc., a Delaware corporation (“Theravance Holdings”), and Triple Royalty Sub II LLC, a Delaware limited liability company (“Triple II”), respectively, to Royalty Pharma Investments 2019 ICAV, an Irish collective asset-management vehicle (“Royalty Pharma”), pursuant to the Equity Purchase and Funding Agreement, dated as of July 13, 2022 (the “Purchase Agreement”), by and between TBPH and Royalty Pharma. The Units represent the right to receive 85% of the royalty payments on worldwide net sales of Assigned Collaboration Products (as defined in the Purchase Agreement) pursuant to the terms of that certain Collaboration Agreement, dated as of November 14, 2002, by and between Innoviva, Inc. (formerly known as Theravance, Inc.), a Delaware corporation (“Innoviva”), and Glaxo Group Limited, a private company limited by shares registered under the laws of England and Wales (“GSK”) (as amended, the “Collaboration Agreement”).



    At the closing of the sale of the Units and the other transactions contemplated by the Purchase Agreement (the “Closing”), TBPH received approximately $l.1 billion in cash and is entitled to up to $250.0 million in cash payments if certain sales-based milestones of the Assigned Collaboration Products are met. Additionally, TBPH will receive from Royalty Pharma 85% of the royalty payments on the Assigned Collaboration Products payable (a) for sales or other activities occurring on and after January 1, 2031 related to the Assigned Collaboration Products in the U.S., and (b) for sales or other activities occurring on and after July 1, 2029 related to the Assigned Collaboration Products outside of the U.S.



    TBPH also received an additional $25.0 million in cash in exchange for certain royalty rights to ampreloxetine, and is entitled to receive an additional $15.0 million upon the first regulatory approval of any pharmaceutical product that contains ampreloxetine as an active pharmaceutical ingredient by either (a) the U.S. Food and Drug Administration or (b) the first of (i) the European Medicines Agency or (ii) all four of Germany, France, Italy and Spain.
  • j
    jung
    Give it a couple of days until the daytraders move out...you will get minimum 40% return from here. Hold on tight to your shares!
  • v
    valuegeek77
    I have seen a lot of weird things in the market

    But never seen stock go down 10% to 600 million market cap after signing $1.1 billion cash, $1.5 billion drug deal.

    Even with outstanding debt, is trading at near cash value with future milestone payments and several other assets valued zero by market (I mean assets that generate sizable revenue)

    Unreal
  • C
    Chris
    Doesn't matter where it is at this moment, shorts in control temporarily and some margin calls on last night's over exuberant long buying. But the longs are going to win out here .
    This NEWS is great financially for TBPH and very soon the price will reflect it.
  • j
    jung
    Absolute minimum buy out price would be $12 ~ $13. Hold on tight to your shares!
  • P
    Pankaj
    Let us go back to 11 plus ......this should be at least 15
  • j
    jung
    What a buying opportunity!
    Buy as much as you can at this manipulated price by shorts. Especially it's an acquisition target by GSK. GSK already owns 13% stake in TBPH. Also SNY is a possible bidder. With a clean balance sheet with a Yupelri pipeline, acquisition target price should be anywhere between $13 and $18.
  • s
    sandi
    Market cap should not exceed cash 💰 on balance sheet 430 million
  • j
    jung
    The only reason that they are cleaning up the balance sheet and retiring all the debts seems like they are readying themselves for the acquisition.
    Again I'm not sure how much it'd be sold for, but it should be around $15.
    absolute minimum price would be $13. Hold on tight to your shares!
  • j
    jojo
    green today
    Bullish
  • M
    Mike
    Horseshoe loves TBPH.
  • M
    Mike
    Listened to the CC. Congrats to the mgmt, very upbeat CC, and justifiably so. The best question was from the BOA analyst. Almost tricking them into a slip of the tongue confession of their setting the company up for a, from my point of view, guaranteed & no brainer buyout.
    Good luck, shorts.
    Bullish
  • A
    Aiaz
    New trader watchlist was published by these guys and it featured TBPH. (http://traderspot.club)
  • R
    Robert
    what happened?
  • s
    slavarussia
    (RVPH) $1.10 ---MC $17 m --Potential Blockbuster Drug in Phase 3 (Schiziphrenia) and multiple Phase 2 ready programs also targeting multi billion dollar markets = 1000%++ opportunity
    https://revivapharma.com/wp-content/uploads/2015/03/Pipeline_01.png

    ###
  • S
    SW
    Feel bad for those that got stopped out at these low levels. What a drag. Some probably don't even know they did.
Advertisement
Advertisement